Abstract
Background
High-dose methotrexate (HD-MTX) therapy has been used to treat a wide range of oncological malignancies. While the therapy can be tolerated with hydration, urine pH control, and leucovorin rescue therapy, HD-MTX is cytotoxic and can cause renal failure. There have been several case reports of HD-MTX toxicity in patients with solid tumors; however, few case series of hematological malignancies have been published. Patients with hematological malignancies tend to be administered many concomitant drugs, which can affect the elimination of MTX and result in acute kidney injury.
Case presentation
Here, we present three cases of HD-MTX-induced acute kidney injury in patients with hematological malignancies. Several blood purification methods were used to attempt to eliminate MTX.
Conclusions
Rapid elimination of MTX is needed for patients with higher serum MTX concentrations to avoid additional cytotoxic effects, especially in patients who have experienced many complications. Although the most effective method for MTX elimination remains unknown, the results of our retrospective survey suggest that combined modalities, such as hemodialysis and plasma exchange, may be suitable for treatment of patients with hematological malignancies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Nagasaki University Hospital, Division of Blood Purification, Nagasaki, Japan (GRID:grid.411873.8) (ISNI:0000 0004 0616 1585); Nagasaki University Hospital, Department of Nephrology, Nagasaki, Japan (GRID:grid.411873.8) (ISNI:0000 0004 0616 1585)
2 Nagasaki University Hospital, Department of Hematology, Nagasaki, Japan (GRID:grid.411873.8) (ISNI:0000 0004 0616 1585)
3 Nagasaki University Hospital, Department of Nephrology, Nagasaki, Japan (GRID:grid.411873.8) (ISNI:0000 0004 0616 1585)
4 Nagasaki University Hospital, Division of Blood Purification, Nagasaki, Japan (GRID:grid.411873.8) (ISNI:0000 0004 0616 1585)
5 Nagasaki University Hospital, Division of Blood Purification, Nagasaki, Japan (GRID:grid.411873.8) (ISNI:0000 0004 0616 1585); National Hospital Organization Nagasaki Medical Center, Department of Urology, Omura, Japan (GRID:grid.415640.2)
6 Nagasaki University Hospital, Department of Respiratory Medicine, Nagasaki, Japan (GRID:grid.411873.8) (ISNI:0000 0004 0616 1585)